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Summary: Insulin-like growth factor-II (IGF-II) may be a prognostic marker in ovarian cancer, and 
its intronic single nucleotide polymorphism (SNP) rs4320932 has been associated with risk of the 
disease. We determined whether rs4320932 is associated with IGF-II expression and patient 
survival in ovarian cancer, and explored whether the SNP variation affects DNA conformation both 
in the absence of and presence of carboplatin. IGF-II genotype (rs4320932) and phenotype were 
analyzed in 212 primary invasive epithelial ovarian cancer tissue samples with Taqman® SNP 
genotyping assays, quantitative reverse transcription–polymerase chain reaction and commercial 
enzyme-linked immunosorbent assay. DNA conformation was evaluated by circular dichroism (CD) 
spectra. Kaplan–Meier survival curves and Cox proportional hazard regression models were used 
to analyze the SNP associations with patient survival. The C allele of rs4320932, previously 
associated with decreased risk of ovarian cancer development, was here associated with 
significantly elevated risks of relapse (Ptrend = 0.0002) and death (Ptrend = 0.0006), remaining 
significant in multivariate analyses. The adjusted hazard ratios were 3.05 (95% confidence interval 
[CI]: 1.47–6.37) for relapse and 3.28 (95% CI: 1.64–6.57) for death, respectively. The variant was 
also significantly associated with chemotherapy response, but not with other clinicopathologic 
variables or with IGF-II expression. DNA with genotypes TT and CC had distinct CD spectra in both 
the absence of and presence of carboplatin. These findings suggest that the intronic SNP 
rs4320932 affects patient survival and chemotherapy response via alteration of DNA 
conformation, but not through regulation of IGF-II expression. This novel finding may have 
implications in individualized medicine for the design of specific molecules targeting DNA of 
specific conformations.  
 
Introduction Insulin-like growth factor-II (IGF-II) is a mitogenic peptide and plays important roles 
in the regulation of cellular proliferation, differentiation and embryonic development in both 
autocrine and paracrine manners (1). The human IGF-II gene is located on the short arm of 
chromosome 11 (11p15.5) and spans approximately 30 kb in length. The gene consists of 10 exons 
and 4 promoters (labeled P1–P4), each promoter driving distinct transcription, producing 
promoter-specific transcripts with unique 5′-untranslated regions. The different promoter- 
specific transcripts share a common translated region based on exons 8, 9 and part of exon 10 (2). 
IGF-II precursors are post-translationally processed to mature peptides, which function as ligands 
of type I IGF receptors, activating IGF signal pathways. Evidence suggests that IGF-II is involved in 
neoplastic transformation and tumor progression of breast, prostate, bladder, colon, gastric and 
ovarian cancers (3–6). Utilization of antibody-blocking IGF signaling is under clinical trial for 
targeted cancer treatment. Higher IGF-II expression is seen in ovarian cancer compared with 
normal ovarian tissue, and IGF-II expression is positively associated with risk of ovarian cancer and 
with poor prognosis (7–10). We have also reported that high IGF-II promoter-specific transcripts, 
particularly P3 and P4, are associated with unfavorable prognosis in ovarian cancer (2). Studies 
have shown that certain women are genetically susceptible to ovarian cancer. High penetrance 
mutations in BRCA1 and BRCA2 occur in about 10–15% of cases (11). Efforts have been made to 
identify single nucleotide polymorphisms (SNPs) associated with ovarian cancer risk (12). Recently, 
from analysis of tag SNPs in the IGF genes, an intronic SNP (rs4320932) of IGF-II was associated 
with ovarian cancer risk (13). Although it is possible that the SNP may be a driver or modifier of IGF 
network signaling, the underlying molecular mechanisms of the genetic association remain poorly 
characterized, and it is yet to be known whether or not the SNP can be utilized as a potential 
marker for prognosis and individualized care in ovarian cancer. DNA secondary structure in its 
double helix conformation has important biological relevance in the physiological processes of cell 
proliferation and apoptosis. DNA conformation can affect the recognition and binding of proteins 
and small ligand molecules (14–16), thereby influencing DNA replication, damage repair and 
apoptosis. DNA sequences and microenvironments are two important determinants in local and 
global DNA conformation (17). Under normal physiological conditions, double-stranded DNA 
constitutes a right-hand B-form double helix (17). Ethanol shifts DNA to adopt a right-hand A-form 
(frequently observed in RNA molecules) in a more compact helical structure (18,19), whereas the 
transition from B-form to left-hand Z-form can occur under certain conditions such as high salt 
concentration (17,20). Cisplatin/carboplatin is a widely used platinum-based chemotherapeutic 
agent in the management of human cancer. Antitumor properties of platinum-based agents 
involve the inhibition of DNA replication and the activation of apoptosis signal pathways through 
binding to DNA to form intra- or interstrand crosslinks with adjacent guanine or adenine bases 
(21,22). The crosslinks cause helical structural distortions and the destruction of nucleotide base 
parallel stacking at platination sites (22–24). However, few studies have reported whether or not 
SNPs affect cisplatin/ carboplatin-induced alterations of DNA conformation. Thus, the purposes of 
this study were to investigate in ovarian cancer the associations of IGF-II genotype (rs4320932) 
with patient survival and with the expression of IGF-II, and to explore whether rs4320932 modifies 
alterations in DNA conformation caused by carboplatin.  
 
Materials and methods Study patients Between October 1991 and February 2000, a clinical study 
was conducted in the Gynecologic Oncology Unit at University of Turin in Italy. Subsequent to 
university institutional review board approval, fresh tumor samples were collected from 212 
patients undergoing surgery for primary invasive epithelial ovarian cancer. The specimens were 
snap frozen in liquid nitrogen immediately after resection, and then transferred to a −80C 
freezer for long-term storage until analysis. Patient clinical and pathology information was 
obtained from the medical charts and pathology reports. The average age of patients at surgery 
was 57.7 years (range: 26–82). Of the 212 patients, 34 (16.0%) had grade 1, 40 (18.9%) had grade 
2 and 137 (64.6%) had grade 3 tumors. Based on the criteria of the International Federation of 
Gynecology and Obstetrics Classification (25), disease stages I–IV were found in 52 (24.5%), 12 
(5.7%), 133 (62.7%) and 14 (6.6%) patients, respectively. The most common histology was papillary 
serous carcinoma (40.1%), followed by endometrioid (19.3%), undifferentiated (17.5%), mucinous 
(8.5%), clear cell (7.6%), mullerian (6.6%) and other (0.5%) according to the World Health 
Organization guidelines (26). After cytoreduction surgery, patients were followed through June 
2001. The median follow-up time was 31 months, ranging from 0.6 to 114 months. Of the 212 
patients, 178 received standard post-operative platinum-based chemotherapy, one had 
chemotherapy without platinum and 33 did not receive chemotherapy due to early stage disease, 
progressive tumor behavior, advanced patient age or severe comorbidity. Each patient was 
evaluated for treatment response based on clinical examination, computed tomography scan and 
CA-125, which was classified into four categories: (i) complete response, resolution of all evidence 
of disease for at least 1 month after the last cycle of chemotherapy; (ii) partial response, a 
decrease of ≥50% in the product of the diameters (maximum and minimum) of all measurable 
lesions without the development of new lesions for at least 1 month; (iii) stable disease, a 
decrease of <50% or an increase of <25% in the product of the diameters of all measurable lesions 
and (iv) progressive disease, an increase of ≥25% in the product of the diameters of all measurable 
lesions or the development of new lesions. Of the 176 patients who had information on response 
to platinum-based chemotherapy, the 128 (72.7%) patients who had complete response were 
considered ‘responders’ in our data analyses, whereas the 48 (27.3%) patients in the other three 
categories (partial response, stable disease and progressive disease) were grouped as ‘non-
responders’. Genomic DNA extraction and IGF-II SNP genotyping Fresh-frozen dissected tumor 
specimens, which, examined by two independent pathologists, contained 80–90% tumor cells, 
were pulverized manually in liquid nitrogen. Genomic DNA was extracted from approximately 100 
mg of tissue powder using a standard phenol–chloroform protocol, and the quality and quantity of 
the extracted DNA samples were determined spectrophotometrically. Genotyping of the IGF-II SNP 
(rs4320932) was performed using the Taqman SNP genotyping assay (Applied Biosystems, Foster 
City, CA) following the manufacturer’s instructions. Briefly, in a volume of 8 μl PCR reaction, 4 μl of 
2 iTaq™ Fast Supermix with ROX (Bio-Rad, Hercules, CA) was mixed with pre-designed Taqman 
primers/probes (Applied Biosystems), approximately 10–50 ng of genomic DNA, and distilled 
water. The PCR conditions were initial denaturing at 95C for 10 min followed by 50 cycles of 
denaturing at 92C for 15 s and annealing/extension at 60C for 1 min. The reactions were 
carried out in an ABI 7500 Real-time PCR System (Applied Biosystems). Ten percent of samples 
were run in duplicate for quality control, with 100% concordance. Analysis of IGF messenger RNA 
levels and peptides Fresh-frozen dissected tumor specimens, which, examined by two independent 
pathologists, contained 80–90% tumor cells, were pulverized manually in liquid nitrogen for 
extraction of total RNA. The quality of ribonuclease-free deoxyribonuclease-treated total RNA was 
determined using 1% agarose gel electrophoresis for the integrity of 18s and 28s ribosomal RNA. 
The messenger RNA (mRNA) levels of IGF-II and promoter-specific transcripts of the IGF-II gene 
were evaluated using SYBR green-based real-time PCR as reported previously (2,10). The 
quantitative PCR was performed in the Chromo4TM Real-time PCR System (MJ Research, 
Waltham, MA). Briefly, in a 20 μl of PCR reaction volume, 1 μl of complementary DNA template 
was mixed with 10 μl of 2 Power SYBR PCR master mix (Applied Biosystems), 200 nM of paired 
primers of either target gene or glyceraldehyde 3-phosphate dehydrogenase as an internal control 
and distilled water. The PCR amplification included initial incubation at 50C for 2 min, denaturing 
at 95C for 10 min, 40 cycles of denaturing at 95C for 15 s and annealing at 60C for 1 min. 
Melting curves were analyzed after each run to verify the size of the PCR product. Each sample 
was analyzed in duplicate, and the analysis was repeated for samples with CV over 5%. Tissue 
levels of IGF-II peptides were evaluated using a commercial Enzyme- Linked Immunosorbent Assay 
Kit (Diagnostic Laboratories Systems, Webster, TX) following the manufacturer’s directions. To 
adjust for the amount of tissue used for protein extraction, we measured the concentration of 
total protein in each specimen using the bicinchoninic acid method (Pierce, Rockford, IL). 
Preparation of double-stranded DNA amplicons A set of primers complementary to the upstream 
and downstream sequences of the SNP rs4320932 (T/C) was designed. The sequences of the 
forward and reverse primers were 5′-CAA CAC ATG CCA GAT TTG AAT C and 5′-CCT GTG TTG GGA 
TTT AAT TGT C, respectively. PCR reactions were performed using 2 HotstarTaq master mix 
(Qiagen, Valencia, CA), with primers each in final concentration of 200 nM, and genomic DNA 
templates extracted from individuals with either homozygous wild-type (TT) or variant (CC) 
genotypes. The PCR thermal conditions consisted of initial activation at 95C for 15 min, 40 cycles 
of denaturation at 95C for 30 s, annealing at 55C for 30 s and extension at 72C for 1 min. A 
final extension was performed at 72C for 10 min. The PCR procedure amplified 160 bp products 
that were then isolated through agarose gel electrophoresis and purified with the Qiaquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s protocol, and the purified products were 
used as templates for sequencing at the Yale University Keck Core Sequencing Facility to confirm 
their sequence identities, as well as for conformation analysis. The amount of purified PCR product 
was determined with a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, 
DE). Circular dichroism spectroscopy and DNA secondary structure comparison Using circular 
dichroism (CD) spectroscopy as described previously (27), we compared experimentally the DNA 
secondary structures between the purified PCR products carrying the homozygous wild-type 
genotype versus the variant one so that we could differentiate the alterations of DNA structure 
due to the SNP. The denatured oligonucleotides (~82 ng/μl in 10 mM Tris–HCl buffer, pH 8.5), in 
duplicate for each genotype, were annealed for 1 h at 37C, followed by incubation overnight at 
37C in the absence or presence of carboplatin (equal molar ratio of DNA to carboplatin; 0.8 μl of 
0.27 nmol/μl carboplatin in dimethyl sulfoxide was added). The incubated DNA oligos were 
analyzed with a ChirascanTM CD spectrometer (Applied Photophysics, Surrey, UK). The CD spectra 
in wavelengths ranging from 220 to 310 nm were acquired at 6C in 1.00 mm Quartz cuvettes 
with bandwidth of 0.5 nm and 0.9 s of time per point. Each sample was run three times to obtain 
the CD spectra in millidegrees (ellipticity), which was adjusted with the CD spectrum of the Tris–
HCl (10 mM) buffer alone as a blank control (there was no difference in CD spectra in the 
wavelengths ranging from 220 to 310 nm between the buffer alone and buffer plus dimethyl 
sulfoxide [~0.4%, v/v]). The average and standard deviation per sample was calculated based on 
six measurements. Graphs of the CD spectra show ellipticity (θ) as a function of wavelength (λ). 
The positions of peaks and the curve shape represent conformations of double-stranded DNA. The 
B-form CD spectrum, characterized by a positive peak between 260 and 280 nm, and a negative 
peak between 240 and 250 nm, is the most frequently observed CD spectrum for a typical double-
stranded DNA molecule (17). The position and intensity (ellipticity, which is proportional to the 
difference between absorbance of left circularly polarized and right circular polarized light) of 
peaks are associated with chromophores (bases) and conformational properties (α-helix rotation 
and the number of base pairs per turn) (17,28). Statistical analysis Expression index was calculated 
for the expression of a target gene using the formula: 1000  2(−ΔCt), where ΔCt = Ct (IGF-II) – Ct 
(glyceraldehyde 3-phosphate dehydrogenase). Chi-square tests or Fisher exact tests were used to 
determine the associations between the IGF-II SNP genotype and clinical and pathologic variables. 
Survival analysis was performed to assess the association of IGF-II genotype with risk of disease 
progression and mortality using Cox proportional hazards regression models and Kaplan–Meier 
survival curves. Wilcoxon rank sum tests were carried out to analyze cis-acting regulatory 
expression quantitative trait loci (eQTL) in IGF-II based on the SNP expression data. All statistical 
analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All P-values are two-
sided. The bold values in tables are statistically significant (P < 0.05).  
 
Results Associations of IGF-II genotype with disease characteristics Table I presents the 
associations between IGF-II (rs4320932) genotype and ovarian cancer characteristics. Therein, we 
observe no associations between rs4320932 genotype and either disease stage, tumor grade or 
histologic type. A lack of association was also seen with debulking result and residual tumor size. 
However, the SNP genotype was significantly associated with response to chemotherapy (Ptrend = 
0.028). In patients who had complete response to chemotherapy, only 3.1% (n = 4) were found to 
have CC genotype, whereas in patients who did not so respond, CC genotype frequency was 
16.7%. The significant association between the genotype and response to chemotherapy remained 
in the subgroup of patients who had residual tumor (P = 0.014 and Ptrend = 0.017; data not 
shown). Associations of IGF-II genotype with patient survival Kaplan–Meier survival curves showed 
that patients with the wild-type genotype (TT) had better survival than those with variant 
genotypes (P < 0.0001 for overall survival and P = 0.0004 for disease progression- free survival, 
respectively; Figure 1A and B). The median overall survivals were 68.9 months (95% confidence 
interval [CI]: 46.6–∞), 40.2 months (95% CI: 32.7–∞) and 18.5 months (95% CI: 7.3–30.1) for TT, 
TC and CC, respectively. Patients with wild-type TT and variant TC and CC genotypes had median 
progression-free survivals of 72.0 months (95% CI: 32.6–∞), 24.2 months (95% CI: 14.8–44.1) and 
11.9 months (95% CI: 7.8–21.0), respectively. To adjust for potential confounding of patient age at 
surgery, disease stage, tumor grade, residual tumor size and histological type on the SNP 
associations with survival, we performed multivariate Cox proportional hazard regression analysis 
(Table II). Compared with patients with TT genotype, those with TC and CC genotypes had higher 
adjusted mortality hazard ratios (adj-HRs), 1.48 (95% CI: 0.94–2.34) and 3.28 (95% CI: 1.64–6.57), 
respectively. The trend in risk was significant (P = 0.001). Similarly, patients with genotypes TC and 
CC had higher risks of relapse than those with TT: adj-HRs 1.76 (95% CI: 1.14–2.71) and 3.05 (95% 
CI: 1.47–6.37), respectively (Ptrend = 0.0004). We also analyzed the genotype association with 
survival according to the dominant model. Significantly increased risks of relapse and death were 
observed for the variant genotypes (TC/CC); the adj-HRs were 1.92 (95% CI: 1.28–2.88) and 1.74 
(95% CI: 1.15–2.65), respectively. Associations of IGF-II genotype and expression Table III presents 
the medians and ranges (5th–95th) of expression of IGF-II total, and P1, P2, P3 and P4. No 
significant associations were found between genotype and IGF-II expression or promoter-specific 
transcripts. Effects of rs4320932 and carboplatin on local DNA secondary structure CD analyses 
showed that in the absence of carboplatin, both wildtype (TT) and variant (CC) DNA had the typical 
B-form CD spectrum but differed in maximum intensity by a 1.5 nm shift in the maximal CD 
wavelength (Figure 2A). Genotype TT had a positive maximum intensity (mean = 2.18 mdeg, 
standard error of mean [SEM] = 0.026 mdeg) at wavelength 274.5 nm, whereas variant CC had a 
maximum intensity (mean = 1.89 mdeg, SEM = 0.039 mdeg) at wavelength 276 nm. The difference 
in maximum intensity is statistically significant (P = 8.6  10−5). Both genotypes had negative 
peaks at wavelength 245 nm. The TT form had a statistically significant deeper negative peak 
(mean = −2.52 mdeg, SEM = 0.088 mdeg) compared with CC (mean = −2.26 mdeg, SEM = 0.070 
mdeg; P = 0.041). The CD spectra also showed that carboplatin caused alleledependent alterations 
in DNA conformation. Carboplatin treatment led to a reduction in maximum intensity and the 
appearance of positive shoulders in both genotypes (Figure 2B and C); however, different 
positions of the shoulders were found according to SNP genotype. For the carboplatin-treated 
DNA with genotype CC, the intensity of one shoulder at wavelength 276 nm (mean = 1.88 mdeg, 
SEM = 0.062 mdeg) was not significantly different (P = 0.96), whereas the intensity of another at 
wavelength of 279.5 nm (mean = 1.69 mdeg, SEM = 0.048 mdeg) was significantly lower than the 
maximum intensity of the naive (untreated) DNA (P = 0.010). Moreover, we also found a 
significant reduction of the minimal intensity (mean = −2.49 mdeg, SEM = 0.058 mdeg) at 
wavelength 242.5 nm (a 2.5 nm shift) for the carboplatin-treated genotype CC DNA compared with 
the naive DNA (P = 0.026; Figure 2B). For the drug-treated DNA carrying genotype TT, one 
shoulder was located at wavelength 282.5 nm (mean intensity = 1.89 mdeg, SEM = 0.058 mdeg) 
and another at 274.5 nm (mean intensity = 1.99 mdeg, SEM = 0.067 mdeg; Figure 2C). Compared 
with the maximum intensity of the naive DNA, the intensities of the two shoulders in the 
carboplatin-treated TT genotype DNA were significantly lower (P = 0.001 and P = 0.023, 
respectively). Although the minimal intensity (mean = −2.66 mdeg, SEM = 0.065 mdeg) at the 
negative band was smaller for the carboplatin-treated genotype TT DNA than for the naive DNA, 
the difference was not statistically significant (P = 0.22). Additionally, the minimal intensity 
remained at wavelength 245 nm.  
 
Discussion In this study, we demonstrated that the intronic SNP rs4320932 in the IGF-II gene was 
associated with patient survival in epithelial ovarian cancer. Patients carrying variant genotypes of 
rs4320932 had higher risks of relapse and death; the associations were independent of other 
prognostic indicators including patient age at surgery, disease stage, tumor grade, histologic type 
and residual tumor size. To our knowledge, this is the first study to show an IGF-II SNP potentially 
involved in the prognosis of ovarian cancer. Interestingly, the direction of the SNP association with 
relapse and death was opposite to the direction of the genotype association with ovarian cancer 
risk. Pearce et al. (13) reported that the rs4320932 variant was a protective factor for ovarian 
cancer in their twophase case-control study. This discrepancy suggests that the rs4320932 variant 
may play different roles in cell transformation and tumor progression. In tumorigenesis, 
rs4320932 may be a passenger rather than a driver because rs4320932 is an intronic SNP, not 
located in the predicted regulation regions of IGF-II transcription, based on genome browser data 
(http://genome.ucsc.edu; data not shown). It has been reported that IGF-II expression is 
associated with the sensitivity of cancer cells to platinum drugs. Overexpression of IGF-II leads to 
cell resistance to platinum agents (29–31). In this study, we found that the SNP rs4320932 of IGF-II 
was associated with chemotherapy response: patients with genotype CC had worse response to 
chemotherapy than those with genotype TT. However, our eQTL analyses did not show a 
significant association of rs4320932 with IGF-II expression. These findings prompted us to ask 
whether or not different response to platinum-based chemotherapy between two genotypes 
could be due to different DNA conformations. Indeed, we found different CD spectra between 
genotype TT and CC DNAs, suggesting that the two genotypes may have different DNA 
conformations. This difference in conformation may affect the binding of chiral drugs and 
formation of crosslinks. One possibility is that the TT genotype has a more favorable DNA 
conformation to facilitate the binding of carboplatin and paclitaxel, both of which are chiral 
molecules. Several studies have reported that different DNA conformations can interfere with the 
binding of paclitaxel, thereby affecting its actions (32–34). Zhao et al. (35) also reported that chiral 
compounds target DNA in both a sequence- and conformation-specific manner. Furthermore, we 
found that carboplatin can induce alterations of DNA conformation, distorting DNA structures 
(helical bend and base stacking, as well as major groove in which protein binding sites are usually 
located) due to the formation of intra- and inter-strand crosslinks (22,36,37). Interestingly, the 
alterations of CD spectra are different between genotypes TT and CC, suggesting the structural 
alterations may be SNP dependent. This difference in structure caused by drug binding and SNP 
genotype may further affect recognition and binding of other regulatory proteins or molecules, 
thereby influencing the processes of DNA replication and repair, as well as cell apoptosis. One 
structure may have a higher affinity for the binding of proteins to DNA than the other, thereby 
affecting downstream biological processes. This assumption is supported by the findings in the Kim 
study (38), which showed that a single C-G transversion can cause the alteration of binding affinity 
of proteins to DNA. In this study, we did not find statistically significant association between the 
genotype of rs4320932 and IGF-II expression. This finding is consistent with the eQTL result 
obtained in lymphoblastoid (LCLs) and NCI-60 cell lines in the SCAN database (http:// 
www.scandb.org/newinterface/about.html) (39), suggesting it is not likely that the lack of 
association between rs4320932 and IGF-II expression is due to mask by the heterogeneity of 
tumor tissues in this study. We searched tagSNP in the region of 200 kb surrounding the SNP 
rs4320932 using HAPMAP (http://hapmap.ncbi.nlm. nih.gov); neither tagSNPs for rs4320932 nor 
this SNP as a tag for other SNPs were found when we chose 0.05 or higher as the minor allele 
frequency and 0.8 or higher as the tagger pairwise R-square. This suggests that based on the 
current knowledge, rs4320932 may not have any tagSNPs affecting IGF-II expression. Because this 
is a single institute study with a relatively small sample size, the findings of this study need further 
validation in independent studies with large sample size. In summary, the results in this study have 
shown the variant of rs4320932 to be associated with elevated risks of disease progression and 
death in epithelial ovarian cancer, and that patients with wild-type alleles have better response to 
chemotherapy than those with variant alleles. Additionally, eQTL analyses did not show 
associations with IGF-II expression. However, different DNA conformations were found in the 
region surrounding rs4320932 according to genotypes TT and CC in the absence and presence of 
carboplatin. These findings suggest that rs4320932 is a potential prognostic marker in epithelial 
ovarian cancer, and that the variation of rs4320932 in IGF-II may affect local DNA conformation, 
thereby modulating the effect of chemotherapy.  
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